AbTis is a biotechnology company with a proprietary linker platform, AbClick®, which enables the development of site-selective antibody conjugate therapies for the targeted delivery of diverse therapeutic payloads.
Through AbClick®, AbTis has established a simple yet cost-efficient conjugation process that empowers the expansion of diverse forms of bioconjugate treatments, such as ADC, ARC, DAC, and others, all without modifying the antibody. AbClick® also allows for precise control over key parameters such as half-life, DAR, and linker-payload stability, which are all essential for designing optimal bioconjugate therapies.
AbClick® is applicable to the native, commercial off-the-shelf, or novel antibodies under development as it requires no mutation or engineering to the antibody itself.
Core competency is as follows.
- Drug/payload conjugation to the unmodified mAb
- Site-selective conjugation leading to precise control over DAR and half-life
- Diversity of payload (both conventional and novel) including dual payload applications
- Stability of linker-payload (minimize off-target, extracellular release of the payload)
Company Details
- Employees
- 16
- Address
- 21, Geumhwa-Ro 105beon-Gil, Giheung-Gu, Yongin-Si,gyeonggi-Do,korea, Republic Of
- Industry
- Biotechnology
- Website
- http://abtis.co.kr
- HQ
- Yongin-si, Gyeonggi-do
Abtis | 앱티스 Questions
Abtis | 앱티스's website is http://abtis.co.kr
Abtis | 앱티스's LinkedIn profile is https://kr.linkedin.com/company/abtis-co
Abtis | 앱티스 has
16 employees.
View email and phone details for 16
employees at Abtis | 앱티스.
Abtis | 앱티스's industry is
Biotechnology
Abtis | 앱티스's top competitors are
Expecto Health Science,
Amc Sciences,
Acepodia,
Ipa (Immunoprecise Antibodies),
Wuxi Xdc,
Alphamab Oncology,
Abtis,
Sutro Biopharma, Inc.,
G2gbio,
Aevisbio, Inc.
Abtis | 앱티스's categories are Biotechnology
